{
    "clinical_study": {
        "@rank": "45389", 
        "arm_group": [
            {
                "arm_group_label": "LMP2A-loaded conventional DC vaccine", 
                "arm_group_type": "Active Comparator", 
                "description": "Epstein-Barr virus (EBV) derived tumor antigen, LMP2 loaded DC vaccine"
            }, 
            {
                "arm_group_label": "LMP2A-loaded conventional DC vaccine + DUK-CPG-001", 
                "arm_group_type": "Experimental", 
                "description": "Epstein-Barr virus (EBV) derived tumor antigen, LMP2 loaded DC vaccine co-administered with a Toll-like receptor 9 (TLR9) ligand, DUK-CPG-001"
            }
        ], 
        "brief_summary": {
            "textblock": "This is a non-blinded, not placebo controlled, randomized, parallel phase 2 pilot study to\n      evaluate the immunological response and the safety of Epstein Barr Virus (EBV)-derived tumor\n      antigen, Latent Membrane Protein-2 (LMP2)-loaded dendritic cell (DC) vaccines alone or\n      co-administered with the TLR9 ligand, DUK-CPG-001, in patients with EBV+  lymphoma in the\n      setting of autologous stem cell transplant with infusion of mature T cells.  Patients will\n      be randomized to receive vaccine alone or vaccine co-administered with the TLR9 ligand,\n      DUK-CPG-001.  Randomization will be stratified by 2 disease types: Hodgkin lymphoma and\n      non-Hodgkin lymphoma."
        }, 
        "brief_title": "Phase II Trial to Evaluate an EBV-derived Dendritic Cell Vaccine in Autologous Stem Cell Transplant", 
        "completion_date": {
            "#text": "September 2024", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Hodgkin Lymphoma", 
            "Non-Hodgkin Lymphoma"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Hodgkin Disease", 
                "Lymphoma", 
                "Lymphoma, Non-Hodgkin"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patient must have a histologically proven diagnosis of any EBV+ Hodgkin or\n             non-Hodgkin lymphoma\n\n          -  EBV positive will be defined as positive if LMP1 or 2 or EBER are positive.  As long\n             as EBV positive on a prior biopsy, EBV testing will not be required at the time of\n             relapse. However, if EBV testing performed on a more recent biopsy and it is\n             negative, that patient will be excluded.\n\n          -  Patients must have had persistent, relapsed, or refractory disease to at least one\n             prior regimen with plans to proceed to autologous stem cell transplant\n\n          -  Patients must be in a complete remission at time of initial pheresis for vaccine\n             preparation; complete remission will be determined using Cheson Criteria100\n\n          -  There are no limits on the number of prior therapies allowed\n\n          -  Able to give voluntary written informed consent\n\n          -  Female subject is either post-menopausal or surgically sterilized or willing to use\n             an acceptable method of birth control (i.e., a hormonal contraceptive, intra-uterine\n             device, diaphragm with spermicide, condom with spermicide, or abstinence) for the\n             duration of the study therapy and for 3 months after vaccine #2.\n\n          -  Male subject agrees to use an acceptable method for contraception for the duration of\n             the study therapy and for 3 months after vaccine #2.\n\n          -  Patients must be 18 years of age or older.\n\n          -  Eastern Cooperative Oncology Group (ECOG) performance status 0-2.\n\n        Exclusion Criteria:\n\n          -  An estimated or measured creatinine clearance of less than 30 ml/min.\n\n          -  Aspartate aminotransferase (AST), alanine aminotransferase (ALT), total bilirubin > 3\n             times the upper limit of normal\n\n          -  Patients on chronic immunosuppressive therapy for any reason (other than chemotherapy\n             for HL)\n\n          -  Chronic systemic steroid therapy at doses greater than 10mg/day of prednisone or its\n             equivalent.\n\n          -  Female subject is pregnant or lactating.  Confirmation that the subject is not\n             pregnant must be established by a negative serum beta human chorionic gonadotropin\n             (beta hCG) pregnancy test result within 48 hours of enrollment.  Pregnancy testing is\n             not required for post-menopausal or surgically sterilized women.\n\n          -  Patient has received other investigational drugs for this disease within 14 days of\n             enrollment\n\n          -  Serious medical or psychiatric illness likely to interfere with participation in this\n             clinical study.\n\n          -  Patients who are HIV positive AND have a CD4 count <50\n\n          -  Prior solid organ transplant or allogeneic stem cell transplant"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "80", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 8, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02115126", 
            "org_study_id": "Pro00042574"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "LMP2A-loaded conventional DC vaccine", 
                    "LMP2A-loaded conventional DC vaccine + DUK-CPG-001"
                ], 
                "intervention_name": "LMP2A-loaded conventional DC vaccine", 
                "intervention_type": "Biological"
            }, 
            {
                "arm_group_label": "LMP2A-loaded conventional DC vaccine + DUK-CPG-001", 
                "intervention_name": "DUK-CPG-001", 
                "intervention_type": "Biological"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "April 14, 2014", 
        "location": {
            "contact": {
                "email": "anne.beaven@duke.edu", 
                "last_name": "Anne W Beaven, MD", 
                "phone": "919-684-8964"
            }, 
            "contact_backup": {
                "email": "annie.tsui@duke.edu", 
                "last_name": "Annie Tsui, BSN, MSN", 
                "phone": "919-681-4769"
            }, 
            "facility": {
                "address": {
                    "city": "Durham", 
                    "country": "United States", 
                    "state": "North Carolina", 
                    "zip": "27710"
                }, 
                "name": "Duke University Medical Center"
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Randomized Phase II Trial to Evaluate an EBV Derived Dendritic Cell (DC) Vaccine When Administered Alone or Co-administered With the TLR9 Agonist, DUK-CPG-001, in EBV+ Lymphoma in the Setting of Autologous Stem Cell Transplant", 
        "overall_official": {
            "affiliation": "Duke University", 
            "last_name": "Anne Beaven, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "September 2024", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Immune response will be defined as an increase in number of spots to 25-fold more than at baseline, and at least 200 spots per 105 cluster of differentiation 8 (CD8)+ T cells, by Day 7 post 2nd vaccination (i.e., a patient with a baseline of 1 spot/105 CD8+ T cells who achieved 25 spots/million would not be counted as a response).\n\"Spots\" are the readout for immune activation measured by the enzyme-linked immunosorbent spot (ELISPOT) assay. Each spot is indicative of an activated T cell that secrete interferon (IFN)-gamma, a cytokine produced by activated T cells.", 
            "measure": "Immune response", 
            "safety_issue": "No", 
            "time_frame": "7 days post 2nd vaccination"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02115126"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Duke University Medical Center", 
            "investigator_full_name": "David Rizzieri, MD", 
            "investigator_title": "Professor of Medicine", 
            "responsible_party_type": "Sponsor-Investigator"
        }, 
        "secondary_outcome": [
            {
                "measure": "Number of patients with greater than grade 1 toxicity", 
                "safety_issue": "Yes", 
                "time_frame": "30 days post last dose of vaccine"
            }, 
            {
                "measure": "Duration of the presence of long term memory cells", 
                "safety_issue": "No", 
                "time_frame": "7 days post second dose of vaccine"
            }, 
            {
                "measure": "Duration of multi-functional CD8 T cell responses", 
                "safety_issue": "No", 
                "time_frame": "7 days post second dose of vaccine"
            }, 
            {
                "measure": "Duration of Th1, Th2 and Th17 cluster of differentiation 4 (CD4) T cell responses as well as CD4+cluster of differentiation 25 (CD25)+Foxp3+ regulatory T cell (Treg) responses", 
                "safety_issue": "No", 
                "time_frame": "7 days post second dose of vaccine"
            }, 
            {
                "description": "Number of days from PBSC transplant until disease relapse or death", 
                "measure": "Disease free survival", 
                "safety_issue": "No", 
                "time_frame": "up to 10 years"
            }
        ], 
        "source": "Duke University", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "David Rizzieri, MD", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "September 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}